TY - JOUR T1 - EGFR tyrosine kinase inhibitors <em>versus</em> chemotherapy in <em>EGFR</em> wild-type pre-treated advanced nonsmall cell lung cancer in daily practice JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00514-2017 VL - 50 IS - 2 SP - 1700514 AU - Pascale Tomasini AU - Solenn Brosseau AU - Julien Mazières AU - Jean-Philippe Merlio AU - Michèle Beau-Faller AU - Jean Mosser AU - Marie Wislez AU - L'Houcine Ouafik AU - Benjamin Besse AU - Isabelle Rouquette AU - Didier Debieuvre AU - Fabienne Escande AU - Virginie Westeel AU - Clarisse Audigier-Valette AU - Pascale Missy AU - Alexandra Langlais AU - Frank Morin AU - Denis Moro-Sibilot AU - Gérard Zalcman AU - Fabrice Barlesi Y1 - 2017/08/01 UR - http://erj.ersjournals.com/content/50/2/1700514.abstract N2 - Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are approved for second-line treatment of EGFR wild-type (EGFR-wt) nonsmall cell lung cancer (NSCLC). However, results from randomised trials performed to compare EGFR-TKIs with chemotherapy in this population did not show any survival benefit. In the era of immunotherapy, many drugs are approved for second-line treatment of EGFR-wt NSCLC and there is a need to reassess the role of EGFR-TKIs in this setting.The Biomarkers France study is a large nationwide cohort of NSCLC patients tested for EGFR mutations. We used this database to collect clinical, biological, treatment and outcome data on EGFR-wt patients who received second-line treatment with either EGFR-TKIs or chemotherapy.Among 1278 patients, 868 received chemotherapy and 410 received an EGFR-TKI. Median overall survival and progression-free survival were longer with chemotherapy than with an EGFR-TKI. Overall survival was 8.38 versus 4.99 months, respectively (hazard ratio 0.70, 95% CI 0.59–0.83; p&lt;0.0001) and progression-free survival was 4.30 versus 2.83 months, respectively (hazard ratio 0.66, 95% CI 0.57–0.77; p&lt;0.0001).This study is helpful to guide a multiline treatment strategy for EGFR-wt NSCLC patients. Immunotherapy is approved for second-line treatment. For third-line treatment, chemotherapy results in longer overall survival and progression-free survival, and should be preferred to EGFR-TKIs.Biomarkers France study: second-line chemotherapy gave longer PFS and OS than TKI in NSCLC EGFR-wt patients http://ow.ly/rEXk30b3tak ER -